Oncobiologics Teams Up With InVentiv On Biosimilar Development
This article was originally published in The Pink Sheet Daily
Executive Summary
The New Jersey biotech has found ways to cut costs of clinical trials by sharing the risk/reward with partners in hopes of bringing a slate of biosimlars to market beginning in early 2017.